Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D07001 and Xeloda/TS-1 in Advanced Biliary Tract Cancer
NCT05065957Phase 3Terminated
- Sponsor
- InnoPharmax Inc.
- Start
- Mar 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of D07001-F4 in biliary tract cancer (BTC), sponsored by InnoPharmax Inc.. Started Mar 2022; status: terminated.
02
Drugs
D07001-F4
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05065957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05065957.